Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Nov 17;17(1):144.
doi: 10.1186/s12933-018-0790-0.

A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats

Affiliations
Comparative Study

A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats

Aysegul Durak et al. Cardiovasc Diabetol. .

Abstract

Background: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect.

Methods: A 28-week high-carbohydrate diet-induced MetS-rats received DAPA (5 mg/kg), INSU (0.15 mg/kg) or vehicle for 2 weeks. To validate MetS-induction, we monitored all animals weekly by measuring body weight, blood glucose and HOMO-IR index, electrocardiograms, heart rate, systolic and diastolic pressures.

Results: DAPA-treatment of MetS-rats significantly augmented the increased blood pressure, prolonged Q-R interval, and low heart rate with depressed left ventricular function and relaxation of the aorta. Prolonged-action potentials were preserved with DAPA-treatment, more prominently than INSU-treatment, at most, through the augmentation in depressed voltage-gated K+-channel currents. DAPA, more prominently than INSU-treatment, preserved the depolarized mitochondrial membrane potential, and altered mitochondrial protein levels such as Mfn-1, Mfn-2, and Fis-1 as well as provided significant augmentation in cytosolic Ca2+-homeostasis. Furthermore, DAPA also induced significant augmentation in voltage-gated Na+-currents and intracellular pH, and the cellular levels of increased oxidative stress, protein-thiol oxidation and ADP/ATP ratio in cardiomyocytes from MetS rats. Moreover, DAPA-treatment normalized the increases in the mRNA level of SGLT2 in MetS-rat heart.

Conclusions: Overall, our data provided a new insight into DAPA-associated cardioprotection in MetS rats, including suppression of prolonged ventricular-repolarization through augmentation of mitochondrial function and oxidative stress followed by improvement of fusion-fission proteins, out of its glucose-lowering effect.

Keywords: Diabetes; Electrophysiology; Heart function; Insulin resistance; Oxidative stress; SGLT2 inhibitors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
General effects of MetS rats treated with either DAPA or INSU. a Body weight (left) and blood glucose level of all groups. b Oral glucose tolerance tests (OGTT) by measuring blood glucose levels before and after orogastric gavage of 1 g/kg glucose administration at 15th min, 30th min, 60th min, 120th min to the rats. c The HOMO-IR index determined as described previously [16]. d The systolic (left) and diastolic (right) pressure changes measured from the tail. e Confirmation of DAPA beneficial effect in MetS rats directly targeting the heart by measuring mRNA levels of SGLT2 in tissue homogenates. Data presenting as mean (± SEM) values. The total number of rats/group; n = 15–17. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group
Fig. 2
Fig. 2
Assessment of in vivo electrical activity of the hearts from DAPA or INSU administrated Mets rats. a Representative in situ ECG traces and b calculated ECG parameters including the R–R and Q–T intervals from DAPA or INSU treated MetS group compared to either MetS or age-matched control rats. c Heart rate was estimated from ECG traces. The representative pressure changes (inset) of the LVDP changes (d) and the rates of pressure development and decay (± dP/dt) of LVDP (e). Data presenting as mean (± SEM) values. The total number of rats/group/protocol; n = 6–7. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group
Fig. 3
Fig. 3
Effects of DAPA or INSU treatment on action potential parameters in freshly isolated cardiomyocytes. a Representative single cell action potential traces for all groups. b Action potential duration (APD) at 25, 50, 75, 90% (APD25, APD50, APD75, APD90) of repolarization are examined from DAPA or INSU treated MetS group compared to MetS and age-matched controls. The current–voltage relations (current–voltage, I–V, characteristics) of voltage-dependent Na+-channels (c) and L-type Ca2+-channels (d) for all groups. The calculated maximum current of Na+-channels (− 40 mV) and Ca2+-channels (0 mV) are given in the lower parts of the graphs as an inset. The total number of cells/group/protocol; n = 6–7. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group
Fig. 4
Fig. 4
Effects of DAPA or INSU treatment on the voltage-dependent repolarizing K+-channel currents in freshly isolated cardiomyocytes. a Demonstration of representative original repolarizing K+-channel traces for all groups. The current–voltage relations (I–V characteristics) of K+ channels (b) and maximum outward (c, + 70 mV) and inward currents (d, − 120 mV) in DAPA or INSU treated MetS rats compared to MetS rats and age-matched control rats. The total number of cells/group/protocol; n = 12–15. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group
Fig. 5
Fig. 5
Changes in Ca2+ transients in DAPA or INSU treated MetS rats compared to MetS rats and age-matched controls rats in Fura-2AM loaded cardiomyocytes. The basal level of Ca2+ in resting cells (a), the representative original Ca2+ transients under electrical stimulation (b, left), the amplitude of transients Ca2+ changes and their corresponding kinetics under electrical-field stimulation (b, right), the time course of Ca2+-transients (c) in DAPA or INSU treated MetS rats compared to MetS rats and age-matched control rats. d Assessment of sarco(endo)plasmic reticulum (SR) Ca2+ content obtained following 10 mM caffeine applications. The total number of cells/group/protocol; n = 19–30. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group. TP time to peak, DT50 decreasing time to 50% relaxation
Fig. 6
Fig. 6
Confocal imaging of intracellular levels of free Na+ and H+ and analysis of mitochondrial function in DAPA or INSU treated MetS rats compared to MetS rats and age-matched controls. The level of free Na+ ([Na]i) estimated in cells loaded with Na+-sensitive SBFI florescent dye (a) and free H+ ([H+]i or [pH]i) with SNARF-1AM (b). The mitochondrial membrane potential (MMP, as FCCP responses) in isolated JC-1 loaded cardiomyocytes (c). The expression levels of mitofusion proteins Mfn-1 and Mfn-2 and their ratio (d). The expression level of mitofission protein Fis-1 (e). The total number of cells/group/protocol; n = 10–19. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group
Fig. 7
Fig. 7
Assessment of oxidative stress status in cardiomyocytes in DAPA or INSU treated MetS rats compared to MetS rats and age-matched controls. Intracellular ROS ([ROS]i) (a) and RNS levels ([RNS]i) (b) imagined with confocal microscopy in cells loaded with either a specific dyes DCFDA or DAF, respectively. Maximal fluorescence intensity was achieved by a HEPES-buffered solution supplemented with H2O2 (100 μM) and NO donor ZipNONO, (100 μM). The free and total protein thiol levels (c) and the ADP/ATP ratio (d) in isolated cardiomyocytes. The total number of cells/group/protocol; n = 15–17. Significance level at *p < 0.05 vs. CON group and #p < 0.05 vs. MetS group

Similar articles

Cited by

References

    1. Serne EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension. 2007;50(1):204–211. doi: 10.1161/HYPERTENSIONAHA.107.089680. - DOI - PubMed
    1. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001;321(4):225–236. doi: 10.1097/00000441-200104000-00003. - DOI - PubMed
    1. Gottdiener JS, Reda DJ, Williams DW, Materson BJ. Left atrial size in hypertensive men: influence of obesity, race and age. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol. 1997;29(3):651–658. doi: 10.1016/S0735-1097(96)00554-2. - DOI - PubMed
    1. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23(5):600–606. doi: 10.1161/01.HYP.23.5.600. - DOI - PubMed
    1. Lauer MS, Anderson KM, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1992;19(1):130–134. doi: 10.1016/0735-1097(92)90063-S. - DOI - PubMed

Publication types

MeSH terms